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Background. Sarcoma is a rare type of cancer with nonspecific symptoms and uncertain aetiology. (us, timely diagnosis of
sarcomas is a clinical challenge. (e aim of this study was to investigate the use of healthcare services 24months preceding a
sarcoma diagnosis compared to a matched cohort. Materials and Methods. (e study was a retrospective, population-based,
matched cohort registry-study. Patients with sarcoma in Denmark in 2000–2013 were identified in the Danish Sarcoma Registry
(n� 2167) and matched 1 :10 on gender, age, and listed general practice. Using a binomial regression model, incidence rate ratios
were calculated for face-to-face contacts in general practice, inpatient and outpatient visits, surgery, paraclinical examinations,
and diagnostic imaging. Analyses were stratified for sarcoma subtypes, grade, stage, gender, and presence of comorbidity. Results.
(e sarcoma patients had significantly increased incidence rate ratios in use of healthcare services compared to the matched
cohort a year before their diagnoses. An increase in consultation rates was seen 11months before diagnosis for inpatient visits,
9months before diagnosis in general practice and outpatient visits, 8months before diagnosis for paraclinical examinations, and 4
and 3months before diagnosis for diagnostic imaging and surgery, respectively. (ere were no clinical significant differences in
length of increased consultation rates between sarcoma type, stage, and grade. Sarcoma patients with comorbidity had persistently
higher consultation rates compared to patients without comorbidity. Conclusions. (e use of healthcare services among sarcoma
patients increased several months before diagnosis in all healthcare sectors. (e results reveal a diagnostic time window and a
potential to refer, diagnose, and treat sarcoma patients in a timelier manner.
1. Introduction
Sarcoma is a rare cancer representing 1% of all newly di-
agnosed malignancies in Denmark [1]. (e aetiology is
generally unknown, and the symptoms mimic many benign
conditions. Delay of diagnosis is well known in sarcomas
and is a recognised problem for many other types of cancer
[2–9]. An earlier diagnosis may have an impact on the size
and stage at diagnosis and thus improve outcome, though
different studies point towards contradictory results
[3, 10–12]. (e introduction of fast-track cancer referral
pathways seems to have reduced the time from referral and
until the sarcoma is finally diagnosed [13].(e largest part of
waiting time before referral to a sarcoma centre can be
ascribed to the patient and the local hospital [14]. (us, the
key to reduce time from symptom to treatment might lie in
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the time before the patient gets referred to a sarcoma centre
[13].
In Denmark, 98% of the residents are listed with a
general practice [15].(eGPs act as gatekeepers to the rest of
the healthcare system and play an important role in pre-
ventive healthcare, screening, diagnosis, treatment, and
referral to practicing specialists or hospitals. (e Danish
healthcare system is tax-funded, and ensures a uniform, free
access to healthcare services regardless of socioeconomic
position [15]. (e aspects of low incidence, nonspecific
symptom presentation, and low symptom awareness may
delay the diagnostic process. Outlining diagnostic activity in
use of healthcare services before sarcoma diagnosis is
therefore a crucial first step in any effort aimed at an early
detection of the disease [2, 3, 5, 16, 17].
(e aim of this study was to investigate the use of dif-
ferent healthcare services 24months preceding a sarcoma
diagnosis compared to a matched cohort, stratified for
sarcoma subtype, grade, stage, gender, and presence of
comorbidity.
2. Materials and Methods
2.1. Study Design and Study Population. (is nationwide
population-based matched comparative study was per-
formed using data from Danish national registries. Treat-
ment of sarcomas in Denmark is centralised in two centres in
Aarhus and Copenhagen. All sarcoma patients are di-
agnosed and treated according to national guidelines by an
experienced multidisciplinary sarcoma team [18, 19].
From the Danish Sarcoma Registry (DSR), we identified
patients ≥15 years of age with a histopathologically verified
soft tissue or bone sarcoma located in the extremities or
trunk wall diagnosed from 1 January 2000 till 31 December
2013 (n � 2167). (e index date was defined as the date of
the final pathology report and the histopathological di-
agnosis of the sarcoma. (e date of diagnosis was chosen
based on the hierarchy produced by the European Network
of Cancer Registries [20]. (e DSR is a validated, national,
population-based clinical database containing all patients
with sarcoma in the extremities or trunk wall from 2000
onwards and holds information on patient characteristics
and detailed data on tumour characteristics, surgical and
oncological treatment, local and distant recurrences, and
death [21, 22].
All Danish residents are assigned a unique civil regis-
tration number (CPR-number) at birth or immigration and
appear in the Civil Registration System (CRS). (is enabled
us to link all data from the DSR and the different Danish
national registries on an individual level [23].
For each sarcoma patient, 10 references matched on age
(±12months), gender, and listed general practice were
identified through CRS and the Patient List Registry (PLR).
(e PLR is an administrative registry where information on
any person registered with a general practice at a given time
is available [15]. Index date was defined as the day of di-
agnosis of the sarcoma patient. Cases or references living
outside of Denmark at some point during the 24-month
period before the index date were ineligible.
A range of healthcare services were selected to estimate
the prediagnostic healthcare activity for both cases and
references. Data from consultations in general practice,
public and private hospitals, and practicing specialists were
retrieved from the National Health Insurance Registry
(NHSR) and the National Patient Registry (NPR). All
Danish healthcare services are registered prospectively in
NHSR with the purpose of remuneration, and data are
therefore practically complete [24]. Admissions, discharge
dates, ICD-10 diagnoses, and data on imaging were obtained
from the NPR. (e NPR is a national population-based
database with a mandatory obligation to report and covers
more than 99% of all Danish hospital admissions [25].
For general practice, monthly rates of face-to-face
contacts in daytime were calculated, including normal
consultations and home visits and excluding specific pre-
ventive consultations and out-of-hours. It was not possible
to gain information regarding reason and the content of the
consultations. For inpatient visits (patients hospitalized for
an undefined period of time and registered as such), out-
patient visits (patients referred to a hospital on an ambulant/
outpatient basis, e.g., directly by the GP), and surgery
(registered surgical procedures), we obtained all discharge
diagnoses within the specialities orthopaedic surgery, der-
matology, and plastic surgery. Paraclinical examinations
ordered by the same range of specialities were obtained as
well. Diagnostic imaging was obtained by extracting data on
registered conducted services from all public and private
departments of radiology.
All of the consultation rates were independent of
whether the patient had symptoms of sarcoma or not
24months prior to their sarcoma diagnosis.
Based on the Charlson Comorbidity Index (CCI) score
obtained from the NPR 10 years prior to the sarcoma di-
agnosis, we divided comorbidity into “no comorbidity” with a
CCI score of 0 and “comorbidity” with a CCI score of ≥1 [26].
Data on tumour characteristics (subtype, grade, stage,
and tumour size) were obtained from the DSR. (e patients
were divided into groups depending on the subtype of
sarcoma (soft tissue sarcoma and bone sarcoma), according
to stage (localised or disseminated disease), grade, and size,
at time of diagnosis. Low-grade sarcoma was defined as
grade I and high-grade sarcoma as grade II + III, according
to the histopathological grading system [27]. (e cutoff
values regarding size were defined as large if soft tissue
sarcoma exceeded 5 cm and bone sarcoma 8 cm, according
to the WHO Classification of Tumours of Soft Tissue and
Bone, fourth edition, and the TNM classifications [28, 29].
2.2. Statistical Analysis. In order to compare the monthly
contact rates, the incidence rate ratios (IRRs) were cal-
culated using a binomial regression model applying robust
variance due to clusters of patients [30]. All IRRs presented
are adjusted for age and gender. All tests were two-sided,
and p values of 0.05 or less were considered statistically
significant. Estimates were made with corresponding 95%
confidence intervals (CI). All analyses were performed in
STATA 14.2 software.
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2.3. Ethical Approval. (e Danish Data Protection Agency
(j.nr: 1-16-02-245-14), Statens Serum Institute (FSEID-1729),
Statistics Denmark (p.nr: 706699), and the Danish Clinical
Registries (j.nr: DSD-2017-03-02) approved this study.
3. Results
3.1. Characteristics of Study Population and Reference
Population. A total of 2167 sarcoma patients (cases) and
21,670 references were included in this study. Characteristics
of the sarcoma cohort and reference population are listed in
Table 1.
3.2. Use of Healthcare Services before Diagnosis. (ere was a
clear increase in overall consultation and examination rates
in the period before the sarcoma diagnosis in the study
population compared to the reference group (Figure 1). (e
IRRs were statistically significant in the 12 consecutive
months preceding diagnosis with a peak in the final month
with an IRR of 13.89 (CI 12.41–15.54).
Face-to-face consultation rates in general practice are
shown in Figure 2(a). (e IRRs were consecutively statis-
tically significantly higher from 9months prior to diagnosis
with a peak in the last month.(e rates of contacts in general
practice increased significantly from 9months prior to di-
agnosis, and general practice was far most the place where
the patients had most contacts. Inpatient and outpatient
visits are shown in Figures 2(b) and 2(c).
Statistically significant increases in IRRs were seen from
11 to 9months prior to diagnosis, respectively.
(e most pronounced difference between the case
population and the references in the month before diagnosis
was in paraclinical examinations with an IRR of 33.1
(Figure 2(d)). Diagnostic imaging had statistically significant
IRRs 4months prior to diagnosis (Figure 2(f )).
3.3. Use of Healthcare Services in Different Subgroups of
Sarcoma Patients. (e overall rates of healthcare services
were higher among bone sarcoma patients compared to soft
tissue sarcoma patients, and the IRRs were statistically
significantly increased in the last four months before di-
agnosis (Figure 3(a)).
(e overall use of healthcare services was very similar
between high- and low-grade sarcoma until the last
3months, where high-grade sarcoma had statistically sig-
nificantly higher IRR (Figure 3(b)).(ere was no statistically
significant difference in IRRs for patients with localised
disease compared to patients with disseminated disease at
the time of diagnosis (Figure 3(c)).
For all 24months, the IRRs in sarcoma patients with
comorbidity were statistically significantly increased except
for the last month before diagnosis (Figure 3(d)).
Women had statistically significantly higher IRR rates in
5 scattered months before diagnosis though no statistically
significant IRRs were found in the last 8months before
diagnosis (Figure 3(e)).
4. Discussion
4.1. Main Findings. (is nationwide, population-based
study of 2167 sarcoma patients showed a marked increase
in use of healthcare services in the period leading up to the
sarcoma diagnosis when compared to a 1 :10 matched
Table 1: Patient characteristics for 2167 sarcoma patients di-
agnosed from 2000 to 2013 in Denmark and 21,670 references
matched on age, gender, and general practice.
Cases References
N (%) N (%)
Total 2167 (100) 21670 (100)
Age (years)
Median (range) 56 (15–96) 56 (14–101)
15–49 759 (35) 7576 (35)
50–69 823 (38) 8297 (38)≥70 584 (27) 5797 (27)
Gender
Female 972 (45) 9752 (45)
Male 1195 (55) 11918 (55)
Sarcoma type
Soft tissue sarcoma 1617 (76) —
Bone sarcoma 509 (24) —
Stage at diagnosis
Localised 1906 (88) —
Disseminated 261 (12) —
Grade at diagnosis
Low grade (I) 509 (26) —
High grade (II + III) 1482 (74) —
Comorbidity
No comorbidity 1741 (80) —
Comorbidity 426 (20) —
N: number. Sarcoma type: 41 missing. Grade: 176 missing.
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Figure 1: Monthly rates and incidence rate ratios (IRRs) for the
total use of healthcare services for references and cases 24months
before the sarcoma diagnosis, with 95% confidence interval (CI).
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(d)
Figure 2: Continued.
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Figure 2:Monthly rates and incidence rate ratios (IRRs) for use of health care services among references and cases in (a) general practice, (b)
inpatient visits, (c) outpatient visits, (d) paraclinical examinations, (e) surgery, and (f) diagnostic imaging for cases and references
24months before the sarcoma diagnosis, with 95% confidence interval (CI). Note the differences in the Y-axis range.
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Figure 3: Continued.
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cohort. In general, an increasing number of contacts were
observed from about one year before a sarcoma diagnosis.
(e rates of contacts in general practice increased sig-
nificantly from 9months prior to diagnosis. (is may be due
to the gatekeeper role and using “wait-and-see” before re-
ferring to further investigation. (e use of healthcare
services in hospital started at nearly the same time about
8months before which may be due to GPs referring the
patient and an increased use of casualty departments.
(ere was a tendency that bone sarcomas were seen more
often in the months leading up to diagnosis compared to
soft-tissue sarcomas, which reflects the symptomatology,
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Figure 3: Monthly rates and incidence rate ratios (IRRs) for use of healthcare services in the case population in (a) sarcoma type, (b) tumour
grade, (c) tumour stage, (d) comorbidity, and (e) gender for cases and references 24months before the sarcoma diagnosis, with 95%
confidence interval (CI). Note the differences in the Y-axis range.
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which may mimic more benign conditions (musculo-
skeletal complaints).
4.2. Strengths and Limitations. Information on all the
contacts in the healthcare system was collected through
nationwide Danish registries with a high level of accuracy
and completeness [31]. (is is due to the mandatory obli-
gation to report events and procedures at the hospitals and
that the registration is the basis for remuneration of the GPs
and private practicing specialists. Sarcomas are rare, but by
using data from DSR, we obtained complete population-
based, nationwide data [21, 22]. Selection bias and in-
formation bias in relation to healthcare services would be
negligible, since the data were not collected for the purpose
of this study. To minimise the risk of confounding, the
references were matched according to age, gender, and
general practice. By matching on general practice, the GP-
dependent and area-specific differences in healthcare
seeking were reduced. (e hospital departments and private
practicing specialists of interest were chosen from a clinical
point of view.(e hypothesis was that a GPmight refer to an
orthopaedic surgeon, a dermatologist, a plastic surgeon, or a
physiotherapist taking the characteristic symptoms of sar-
comas into consideration.
A limitation of this study in terms of qualifying the
number of consultations is the lack of knowledge regarding
the reason and the content of the consultations in both cases
and references and the indication for the referrals. Fur-
thermore, the 24months prior to diagnosis included the use
of healthcare services, i.e., diagnostic imaging, paraclinical
examinations, and biopsies ordered by the department at the
sarcoma referral centre, and hence, the cutoff in diagnostic
workup before and after suspected sarcoma may be vague.
4.3. Comparison with Other Studies. (e statistically sig-
nificant increase in consultation rates in general practice
about 9month before diagnosis may be due to the non-
specific symptom presentation in sarcoma patients and low
incidence, which makes awareness among clinicians and
patients lower. In other types of cancer, the consultation rate
in general practice prior to diagnosis varied quite extensively
[8, 32–35]. Diseases with low incidence and uncharacteristic
symptoms, such as CNS tumours, have a longer period of
increased consultation rates in general practice with
17months before diagnosis, than malignant melanoma with
only three months before diagnosis [33]. It must be noted
that the patients already, and in particular those with
comorbidity, accessed general practice as the most used
healthcare service.
Parallel with the increased use of general practice,
there was a significant increase in use of inpatient and
outpatient visits and paraclinical tests. (is could likewise
be due to the vague symptoms and low awareness of the
disease [14]. Further, it could be an expression of ongoing
diagnosis of the sarcoma, since the general practitio-
ner—in case of a suspected sarcoma—would refer to the
local hospital in the first place. Still, diagnostic imaging
and paraclinical examinations had the latest onset of
activity, about four months before diagnosis, which could
indicate that the sarcoma diagnosis is suspected at this
point.
(ere was a tendency of increased consultation rates
among patients with bone sarcomas compared to those with
soft tissue sarcomas. One of the main symptoms of bone
tumours is an increasing pain over weeks, which could be
part of the reason [36]. As such, being wary of persistent
deep pain from a bone, especially in children and young
adults, is important.
Sarcoma patients with comorbidity had higher consul-
tation rates compared to the sarcoma patients without
comorbidity, which may reflect the habitual difference in
rates of consultations in patients with multimorbidity in the
general population [37, 38]. During the months prior to
diagnosis, the difference (IRR) between patients with or
without comorbidity decreased, indicating that the di-
agnostic workup has the same contents in the two groups.
Comorbidity may mask early cancer symptoms and thus
increase the diagnostic delay and lead to a more advanced
stage by the time the patient is referred to a sarcoma centre
[39]. On the contrary, higher prevalence of comorbidity in
early-stage cancers has been described in other cancers
[40, 41]. GPs and other health professionals should have in
mind that patients with cancer and comorbidity have a
poorer prognosis and thus be aware of multimorbid patients
with aberrant symptoms in order of timely referral
[25, 42, 43].
(e period of increased contacts among sarcoma pa-
tients before diagnosis in general practice is long compared
to other types of cancer [33, 44]. Other studies have found a
median diagnostic interval of 14–16months in sarcoma
patients [2, 45, 46]. In a study of paediatric and adolescent
soft tissue sarcoma patients, the symptom interval ranged
between 1week and 60months and had a negative impact on
survival [47]. (e introduction of cancer fast-track referral
pathways in Denmark has facilitated a more expedited di-
agnosis, and the known defined alarm symptoms were
predictive for sarcoma patients but had a low positive
predictive value in general [13].
One way to reduce the diagnostic interval could be to
give the GP the opportunity to refer directly to a MRI or
CT scan for suspected sarcomas, instead of referring to a
local hospital as today. (is has proven to reduce specialist
time in lung cancer patients [48]. (e advantage is a
shorter route to a sarcoma centre if the scan confirms the
suspicion of the sarcoma diagnosis, but without the
concern among the patients that go through a fast-track
cancer patient pathway. (e disadvantage is the risk of
overburdening the radiology departments, as indicated in
previous studies of other cancer types [48–50]. (e study
of lung cancer patients demonstrated that direct referral to
CT scan did not cause an increase in the number of CTs
performed [48].
Together with better access to imaging, a short rele-
vant update on sarcomas and early diagnosis, timely
referral, and how to select patients for further exami-
nation might be relevant. (is has proven to be relevant in
lung cancer [51].
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5. Conclusion
(is study revealed an increased use of healthcare services
and diagnostic activity in both primary and secondary care
for Danish sarcoma patients in the years leading up to the
diagnosis. Increased contacts in general practice started
nine months before diagnosis and coincided with an in-
creased use of imaging and hospitals. (is reflects a di-
agnostic window where general practice is dependent on a
responsive health care system. (e results indicate that a
diagnostic time window is present, and the potential to
refer, diagnose, and treat sarcoma patients in a timelier
manner exists.
Further studies could focus on the content of the con-
sultations and the indications for and access to further
examinations.
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